DVAX - Dynavax Technologies Corporation
18.65 0.00 (0.00%)
After hours: 7:22PM EDT
| Previous Close | 18.10 |
| Open | 18.15 |
| Bid | 18.65 x 700 |
| Ask | 18.75 x 200 |
| Day's Range | 17.70 - 18.75 |
| 52 Week Range | 5.15 - 24.45 |
| Volume | 846,028 |
| Avg. Volume | 1,519,958 |
| Market Cap | 1.161B |
| Beta | 0.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.81 |
| Earnings Date | May 7, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.83 |
- ACCESSWIRE•13 hours ago
Wired News – CDC Publishes Dynavax’s HEPLISAV-B(R) ACIP Recommendations in Morbidity and Mortality Weekly Report
LONDON, UK / ACCESSWIRE / April 25, 2018 / Active-Investors.com has just released a free research report on Dynavax Technologies Corp. (NASDAQ: DVAX) ("Dynavax"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=DVAX as the Company's latest news hit the wire. On April 23, 2018, the Company announced that the Centers for Disease Control and Prevention (CDC) has published the Advisory Committee of Immunization Practices' (ACIP) Recommendations for the use of HEPLISAV-B® [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for adults in the US, in the Morbidity and Mortality Weekly Report (MMWR) dated April 19, 2018.
- GlobeNewswire•3 days ago
Dynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly Report
BERKELEY, Calif., April 23, 2018-- Dynavax Technologies Corporation today announced that the Centers for Disease Control and Prevention published the Advisory Committee of Immunization Practices’ Recommendations ...
- GlobeNewswire•8 days ago
Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting
Demonstrates potential to achieve long-term, systemic responses Combination therapy was well tolerated Additional SD-101 data in head and neck squamous cell carcinoma presented at AACR. BERKELEY, Calif., ...
- Benzinga•9 days ago
11 Stocks Moving In Monday's After-Hours Session
Gainers: NF Energy Saving Corp (NASDAQ: NFEC ) shares are up 8 percent after a 13-D filing from Bi Yongquan showed a 19.8-percent stake. Dynavax Technologies Corporation (NASDAQ: DVAX ) shares are up ...
- GlobeNewswire•9 days ago
Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck
BERKELEY, Calif., April 16, 2018-- Dynavax Technologies Corporation today announced data from its ongoing Phase 1 b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with ...
- MarketWatch•9 days ago
Dynavax shares rise 14% on promising cancer conference data
Dynavax Technologies Corp. shares rose 14% in premarket trade Monday after the company released promising data in conjunction with the annual American Association for Cancer Research meeting, happening ...
- Benzinga•9 days ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Netflix, Inc. (NASDAQ: NFLX ) stock was trading higher ...
- Benzinga•12 days ago
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
Biotech stocks staged a recovery this week, thanks to a deal in the space and news concerning positive pipeline developments. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) gained 4.26 percent ...
- GlobeNewswire•22 days ago
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif., April 03, 2018-- Dynavax Technologies Corporation today announced that on March 29, 2018 the Compensation Committee of Dynavax’ s Board of Directors approved the grant of inducement stock ...
- Simply Wall St.•28 days ago
What Are Analysts Saying About The Future Of Dynavax Technologies Corporation’s (NASDAQ:DVAX)?
The latest earnings update Dynavax Technologies Corporation’s (NASDAQ:DVAX) released in December 2017 revealed company earnings became less negative compared to the previous year’s level – great news for investors InvestorsRead More...
- GlobeNewswire•last month
Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting
Data from Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Durability Data in Advanced Metastatic Melanoma. BERKELEY, Calif., March 15, 2018-- Dynavax Technologies Corporation announced today ...
- Associated Press•2 months ago
Dynavax Technologies reports 4Q loss
On a per-share basis, the Berkeley, California-based company said it had a loss of 45 cents. Losses, adjusted for amortization costs, came to 43 cents per share. The biopharmaceutical company posted revenue ...
- GlobeNewswire•2 months ago
Dynavax Reports Fourth Quarter and Year End 2017 Financial Results
HEPLISAV-B Launched in the United States. Phase 2 Data in Two Immuno-oncology Programs Planned for First Half 2018. BERKELEY, Calif., March 08, 2018-- Dynavax Technologies Corporation today reported financial ...
- GlobeNewswire•2 months ago
Dynavax to Present at the Cowen & Co. Annual Health Care Conference
BERKELEY, Calif., March 05, 2018-- Dynavax Technologies Corporation announced today that Eddie Gray, Dynavax’ s Chief Executive Officer, will present at the Cowen & Co. 38 th Annual Health Care Conference ...
- Motley Fool•2 months ago
These 3 Stocks Shot Up 100% in 2017 -- Are They Still Buys?
Just because a stock doubles doesn't mean it's time to sell. Very often, it's still worth buying. Find out what the answer is for these three.
- GlobeNewswire•2 months ago
Stanley A. Plotkin, M.D. Steps Down from Board of Dynavax Technologies
BERKELEY, Calif., March 02, 2018-- Dynavax Technologies Corporation announced today that Stanley A. Plotkin, M.D. has indicated his intention to step down from the Board of Directors effective from the ...
- GlobeNewswire•2 months ago
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif., March 01, 2018-- Dynavax Technologies Corporation today announced that on March 1, 2018 the Compensation Committee of Dynavax’ s Board of Directors approved the grant of inducement stock ...
Associated Press•2 months agoUS panel recommends new adult vaccine against hepatitis B
NEW YORK (AP) — A federal advisory panel on Wednesday recommended a new vaccine against hepatitis B.
- Benzinga•2 months ago
Dynavax Clears Heplisav-B Hurdle With CDC Recommendation
What Happened Dynavax Technologies Corporation (NASDAQ: DVAX ) traded up 3.7 percent Wednesday after management announced the Centers for Disease Control and Prevention will recommend HEPLISAV-B as an ...
- MarketWatch•2 months ago
Dynavax stock rises after hepatitis B vaccine recommendation by CDC immunization committee
Dynavax Technologies Corp. shares rose 2.3% in moderate Wednesday morning trade after the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices unanimously voted in ...
- GlobeNewswire•2 months ago
Dynavax’s HEPLISAV-B™ Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults
BERKELEY, Calif., Feb. 21, 2018-- Dynavax Technologies Corporation today announced that the Centers for Disease Control and Prevention’ s Advisory Committee on Immunization Practices voted unanimously ...
- GlobeNewswire•2 months ago
Dynavax Secures $175 Million in Non-Dilutive Debt Financing
Proceeds to be Used to Commercialize HEPLISAV-B™ in United States and Advance Company’ s Immuno-Oncology Product Candidates. Company Deploying HEPLISAV-B Field Sales Team. BERKELEY, Calif., Feb. 20, 2018-- ...
- Benzinga•2 months ago
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
Volatility is the name of the game in profitable trading, and it's all the more relavant in the biotech space, which is subject to many make-or-break catalytic events . This apart, usual market-moving ...
- GlobeNewswire•2 months ago
Dynavax to Present at the RBC Capital Markets Global Healthcare Conference
BERKELEY, Calif., Feb. 14, 2018-- Dynavax Technologies Corporation announced today that Eddie Gray, Dynavax’ s chief executive officer, will participate in a fireside chat at the 2018 RBC Capital Markets ...
- TheStreet.com•2 months ago
Watch These Biotechs and the FDA Calendar
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
